Search results
Recommended therapy algorithm for the treatment of chronic urticaria. wks weeks, mo months, CIndU chronic inducible urticaria. A second-generation non-sedating H1 antihistamine is the first treatment of choice.
- New treatments for chronic urticaria - PubMed
Antihistamines and omalizumab are the mainstay therapies of...
- New treatments for chronic urticaria - PubMed
27 lip 2024 · Treatments that prevent, delay, or slow the progression of chronic urticaria and induce disease remission are needed. This Therapeutics article describes existing unmet medical needs in personalised chronic urticaria treatment and discusses how emerging drugs can address them.
1 cze 2017 · In refractory chronic urticaria, patients can be referred to subspecialists for additional treatments, such as omalizumab or cyclosporine. More than one-half of patients with chronic...
Antihistamines and omalizumab are the mainstay therapies of CU. Additional treatment options are needed. Here, we review the off and beyond label use of licensed drugs, novel treatments that are currently under development, and promising new targets.
8 sie 2022 · The recommendations for the use of first-line treatment (antihistamine), second-line treatment (omalizumab), and third-line treatment (cyclosporine) now include guidance on updosing and duration (Fig 3, A and B).
26 wrz 2024 · The 2022 international urticaria guideline recommends the monoclonal anti-IgE antibody omalizumab as second-line treatment for antihistamine-refractory chronic spontaneous urticaria. However, at least 30% of patients have an insufficient response to omalizumab, especially those with IgG-mediated autoimmune urticaria.
13 paź 2021 · Nonsedating anti-H 1 antihistamines remain the mainstay of treatment for chronic urticaria. If these agents are ineffective, higher dosages may be tried (up to four times the standard...
